Indefinite Delivery Contract 75F40119D10024

This indefinite delivery contract (IDC) was awarded by the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), to the Lovelace Biomedical Research Institute. The contract has a ceiling value of $48,882,666.00 and a period of performance through August 5, 2030. The purpose of this IDC is to obtain pharmacology studies, animal model development, and related services to support NCATS' Division of Preclinical Innovation drug...

The National Institutes of Health's National Institute of Child Health and Human Development awarded an indefinite delivery contract to The Regents of the University of California, San Francisco to conduct clinical trials in support of contraceptive development. With a potential value of $5 million and a period of performance through July 2027, this multiple-award contract enables the agency to issue task orders for phase I-IV contraceptive trials in women and treatment trials for gynecologic...

This Indefinite Delivery Contract is a parent IDIQ vehicle awarded by the National Institutes of Health's National Institute of Neurological Disorders and Stroke to Southern Research Institute, a non-profit research organization. The Pharmacology and Toxicology for Therapeutics Program (PTTP) IDIQ has a total potential value of $174,470,000 and a period of performance through September 12, 2026. Under this IDIQ, Southern Research has been awarded multiple task orders to provide drug discovery,...

This is a multiple award indefinite delivery contract awarded by the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), to conduct safety evaluation and toxicology studies to support drug development. The $48.6 million contract has a 6-year ordering period from June 2024 to June 2030. The contractor, IIT Research Institute (IITRI), a non-profit research organization, will perform in vitro and in vivo exploratory and...

The federal contract IDV award is for "PHARMACOLOGY STUDIES AND ANIMAL MODEL DEVELOPMENT AND RELATED SERVICES FOR DRUG DEVELOPMENT" and was issued by the National Center for Advancing Translational Sciences (NCATS), a civilian agency under the National Institutes of Health (NIH). The multiple-award, indefinite delivery contract has a ceiling value of $48,882,666.00 and a period of performance through August 5, 2030. The prime contractor is Advanced Bioscience Laboratories, Inc....

This $49.9 million Indefinite Delivery Contract was awarded by the National Institute on Drug Abuse (NIDA), a civilian agency, to PPD Development LP, a global contract research organization (CRO) subsidiary of Thermo Fisher Scientific. The contract is for research and development related to clinical studies under NIDA's Blueprint MedTech program, which focuses on medical technology development for nervous system disorders. Under this IDC, PPD will provide a range of services including developing...

The federal contract IDV award is for safety evaluation and toxicology studies and related services to support drug development efforts of the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH). The prime contractor, SRI International, a nonprofit research and development institute, will provide in vitro and in vivo exploratory and Investigational New Drug (IND)-directed toxicology studies for small molecule and biologic...

The National Institute of Allergy and Infectious Diseases awarded multiple Indefinite Delivery/Indefinite Quantity contracts to provide preclinical development support for candidate products and drug development activities ranging from initial discovery to clinical trials. Services are conducted under seven task areas including in vitro testing, synthesis of therapeutic agents, small animal models for HIV/HBV/HCV and mycobacterium, formulation development, preclinical pharmacology and...

The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded multiple indefinite delivery/indefinite quantity contracts to provide preclinical development support for candidate products and drug development activities ranging from initial product discovery to activities required for clinical trials and product licensure. Services will be conducted under seven task areas including in vitro testing, synthesis of therapeutic agents, small animal models for...

This indefinite delivery contract (IDC) was awarded by the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), to Lovelace Biomedical Research Institute, a not-for-profit contract research organization. The $48.6 million multiple-award IDC has a 6-year ordering period from June 2024 to June 2030. The contract aims to procure safety evaluation and toxicology studies and related services to support drug development efforts at NCATS....